Medscape April 1, 2025
Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing new targets and new designs and potentially gaining a foothold in the treatment of solid tumors.
“The ceiling for this technology is incredibly high,” he said. “We’re just now gaining momentum and as some of these next generation designs of CAR T-cells start to show promise, I think that will lead to a flurry of further innovation.”
Brentjens spent most of his career as a physician-scientist at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City but moved to the Roswell Park Comprehensive Cancer Center in...
Today's Sponsors
Today's Sponsor